All research products on this site, including all peptides, are sold strictly for laboratory and research use only, not for human or animal consumption, diagnostic, or therapeutic use. Our tallow skincare products are topical cosmetics. You must be 21 or older to enter.
By entering you confirm you are 21+ and accept these products are for research use only. See our Terms and Disclaimer.
For laboratory research. Sold in 10mg tabs.
Complete the order
Supplies and compounds researchers add to this order
Identity, purity and handling data for this compound, in one place. Tap an identifier to copy it.
A third-party certificate for MK-677 is not published here yet. If your work needs one, ask us before ordering and we will tell you what testing is available for the current lot.
Ask about a certificateFor research use only. Not for human consumption.
MK-677 is not a peptide. Chemically designated ibutamoren, and frequently referenced by its mesylate salt form, MK-677 is classified in pharmacological research literature as a non-peptide, orally bioavailable small molecule that functions as a ghrelin receptor agonist and growth hormone secretagogue. The distinction matters for researchers: growth hormone secretagogue is a functional category that includes both peptide compounds, such as GHRP-6, GHRP-2, hexarelin, ipamorelin, and sermorelin, and non-peptide small molecules like MK-677, and conflating the broader category with the peptide subclass is a common source of confusion in searches on this compound.
Structurally, MK-677 lacks the amino-acid backbone that defines a peptide. Its molecular formula, C27H36N4O5S, with a molar mass of approximately 528.7 g/mol, and its CAS registry number, 159634-47-6, are used across certificates of analysis to confirm compound identity ahead of any research protocol. Because it is a small organic molecule rather than a chain of amino acid residues, MK-677 is grouped separately from peptide-class ghrelin agonists in structural classification schemes, even though both classes are studied for overlapping receptor pharmacology.
In laboratory research, MK-677 is investigated as a ghrelin mimetic: it binds the growth hormone secretagogue receptor, GHS-R1a, with high affinity, engaging the same receptor pathway as endogenous ghrelin but without the rapid enzymatic deacylation that limits native ghrelin's utility as a research tool. Downstream, this receptor activation is studied for its role in pulsatile growth hormone release from the pituitary and subsequent hepatic IGF-1 production, positioning MK-677 as a reference compound in GH/IGF-1 axis research models. Its mechanism is described in the literature strictly in terms of receptor-binding pharmacology and signaling cascades observed in research systems.
Because MK-677 and peptide GH secretagogues converge on the same receptor target, researchers and search queries frequently group them together, which is the likely source of the recurring is MK-677 a peptide question. Peptide secretagogues under research investigation, including GHRP-6, GHRP-2, hexarelin, and ipamorelin, are short sequences of amino acids typically studied as reconstituted research peptides. MK-677 occupies a separate structural class as a non-peptide, orally studied small molecule, a distinction researchers rely on when documenting compound class or designing comparative GHS-R1a studies.
Beyond receptor pharmacology, MK-677 research spans several domains: GH/IGF-1 axis dynamics and pituitary secretory patterns, bone metabolism and turnover biomarkers, nitrogen balance and lean tissue parameters in preclinical models, and sleep architecture, particularly slow-wave and REM sleep stages recorded via polysomnography in research models. Ghrelin receptor pharmacology more broadly, including appetite-signaling pathways studied in animal models, is also a documented area of MK-677 investigation. All such findings are drawn from laboratory and preclinical literature and describe research-model observations rather than outcomes in human users.
MK-677 was originally developed under the research code MK-0677 in the mid-1990s as a non-peptide, orally active alternative to peptide GH secretagogues that otherwise required reconstitution. Published research literature since that period has examined the compound's ghrelin receptor pharmacology and GH/IGF-1 axis effects, building a body of preclinical research literature that continues to inform current laboratory research design.
Optimum ReGen Peptides is a research-use retailer offering MK-677 (ibutamoren). Review available batch reports and contact us for documentation on the specific product and lot. MK-677 is supplied for laboratory research only, not for human or animal use; it is not offered to diagnose, treat, cure, or prevent disease.
The areas where this compound appears in the published research literature.
In laboratory and controlled research settings, MK-677's effects on the GH/IGF-1 axis are typically assessed using serial blood sampling protocols combined with ultra-sensitive GH immunoassays and IGF-1 ELISA. Researchers use deconvolution analysis of GH pulsatility data to characterize changes in pulse amplitude, frequency, and interpulse trough levels following MK-677 administration.
Bone metabolism studies employ dual-energy X-ray absorptiometry (DXA) for bone mineral density measurement, alongside biochemical bone turnover markers (serum osteocalcin, bone alkaline phosphatase, urinary NTx) to characterize MK-677's effects on skeletal remodeling dynamics in research subjects over defined study periods.
Receptor biology experiments use radioligand binding assays with [125I]-labeled ghrelin or GHS peptides in GHSR-1a-expressing cell lines to measure MK-677 binding affinity and competitive displacement. Functional downstream assays measuring cAMP production, intracellular calcium flux, and ERK phosphorylation complete the pharmacological characterization of GHSR agonism in these systems.
This listing supplies MK-677 tablets. Follow the packaging and supplier handling instructions for this formulation; powder reconstitution directions do not establish how a finished tablet should be prepared for an assay.
Before laboratory use, obtain formulation and stability documentation for the specific product and lot. Validate any extraction, solvent, and storage conditions against the research protocol.
MK-677 (Ibutamoren) for sale from Optimum ReGen Peptides, a US research-peptide company with a storefront in Medford, Oregon. It is sold out right now; leave your email above and you will hear when it is back. Every order ships 2-Day Priority Air, a $13 flat rate anywhere in the US, with tracking, or can be picked up at the store.
MK-677 is supplied as tablets, for laboratory and research use only, not for human consumption.
